Skip to content
TrialScanner

NCT03283826

Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis

Phase 1/Phase 2TerminatedATRALead

Registry record

Lead sponsor
Atara Biotherapeutics
Conditions
Primary Progressive Multiple Sclerosis; Secondary Progressive Multiple Sclerosis
Primary completion
Nov 9, 2023Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03283826 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT03283826: Phase 1/2 Study to Evaluate... | TrialScanner